0001493152-22-025981.txt : 20221018 0001493152-22-025981.hdr.sgml : 20221018 20220915160719 ACCESSION NUMBER: 0001493152-22-025981 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anixa Biosciences Inc CENTRAL INDEX KEY: 0000715446 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112622630 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250 CITY: SAN JOSE STATE: CA ZIP: 95118 BUSINESS PHONE: 408-708-9808 MAIL ADDRESS: STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250 CITY: SAN JOSE STATE: CA ZIP: 95118 FORMER COMPANY: FORMER CONFORMED NAME: ITUS Corp DATE OF NAME CHANGE: 20140902 FORMER COMPANY: FORMER CONFORMED NAME: COPYTELE INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

ANIXA BIOSCIENCES, INC.

3150 Almaden Expressway, Suite 250

San Jose, CA 95118

September 15, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

Attn: Tyler Howes

	Re:	Anixa Biosciences, Inc.
		Registration Statement on Form S-3
		Filed September 9, 2022, as amended
		File No. 333-267369

Dear Mr. Howes:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Monday, September 19, 2022, or as soon as thereafter practicable.

	Very truly yours,

	/s/ Dr. Amit Kumar
	Dr. Amit Kumar
	Chairman and Chief Executive Officer

cc:	Ellenoff Grossman & Schole LLP